Dubai Final-v20.indd - World Allergy Organization

ABstrACts
ABstrACts
antihistamines, antileukotriene and immunomodulators like cloroquine, azatioprine, colchicine and steroids, the cyclosporine was
contraindicated by its malignant hypertension.
therefore we decided to begin treatment with omalizumab at doses of 150 mg monthly (total igE 18 Ui/ml) associated to
antihistamine and antileukotriene.
result: After 3 doses of this therapy hives and angioedema remission was obtained and lasted for two months.
Conclusion: the omalizumab can be an option in patients with vasculitic, pressure and autoimmune urticaria resistant to others
management lines, being even safer than steroids and immunomodulators. the low levels of our patient’s total igE make to think
that the effect of this medication is not only ig E dependent as has been suggested by several authors.
2308
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE TrEaTmEnT oF HErEDiTarY angioEDEma
(HaE) aTTaCKS
Craig, t. J. 1 , Zuraw, B. 2 , lumry, W. 3 , Baker, J. 4 , levy, r. 5 , Hurewitz, D. 6 , White, m. 7 , riedl , m. 8 , Busse, P. 9 , Bielory, l. 10 , grant, J. A.
11 12 13 13 13 13 , Kalfus, i. , Broom, C. , Villano, s. , Uknis, m. , tillotson, g. and the Cinryze study group
1 2 3 Penn state University, Hershey, PA. the scripps research institute, la Jolla, CA. Allergy and Asthma specialists, Dallas, tX.
4 5 6 University of michigan, Ann Arbor, mi. Family Allergy and Asthma Center, PC, Atlanta, gA. Allergy Clinic of tulsa, inc., tulsa, OK.
7 8 9 institute for Asthma and Allergy, Wheaton, mD. UClA medical Center, los Angeles, CA. mount sinai school of medicine, new York,
nY. 10UmDnJ - new Jersey medical school, newark, nJ. 11University texas medical Branch, galveston, tX. 12lev Pharmaceuticals,
Plymouth meeting, PA. 13ViroPharma incorporated, Exton, PA.
introduction: nf-C1 inH (Cinryze) is approved in the Us for routine prophylaxis against angioedema attacks in adolescent and adult
patients with HAE. this study evaluated the efficacy and safety of repeat use of nf-C1 inH for the treatment of HAE attacks.
methods: this open-label, multicenter (29 sites) study enrolled 113 subjects with a diagnosis of HAE. Approval was obtained
from WirB and informed consent obtained from all subjects. subjects were eligible to receive nf-C1 inH 1000U iV for attacks of
angioedema at any anatomic location. subjects could receive a second dose of nf-C1 inH 1000U if they had not improved by 60
minutes. Documentation of attack occurred every 15 minutes by diary card. the presence of three consecutive assessments of
improvement constituted relief. safety was monitored by recording AEs, vital signs, virology (HBV, HCV, HiV) and anti-C1 inhibitor
antibody.
results: Of the 113 subjects (aged 2-80 years) in this study, 101 received nf-C1 inH for an acute attack, and were included in the
efficacy analysis. twelve received nf-C1 inH for short-term prophylaxis only. A total of 609 attacks in 101 subjects were treated.
median time to beginning of relief of the first attack was 45 minutes. Of 84 laryngeal attacks, none required intubation after receipt
of nf-C1 inH. no difference was observed in subject response between children and adults. in subjects treated for >1 attack the
efficacy of nf-C1 inH was not reduced; of 15 subjects who had ≥ 10 attacks, the median time to beginning of relief of their 10th
attack was 30 minutes. Adverse events were reported in 41% (46/113) of subjects. the majority (87%) were of mild or moderate
intensity. the most common (3%-5% of subjects) were sinusitis, nasopharyngitis, streptococcal pharyngitis, HAE, constipation,
cough, rash, and bronchitis. there were no severe hypersensitivity reactions, including anaphylaxis, related to nf-C1 inH. HBV, HCV,
and HiV testing revealed no evidence of viral transmission. there was no evidence of development of clinically relevant anti-C1 inH
antibodies.
Conclusion: nf-C1 inH was safe and effective for the treatment of all HAE attacks. For subjects with >1 attack, the efficacy of nf-C1
inH for the treatment of HAE did not diminish with subsequent repeated administration.
2309
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE ProPHYlaXiS oF HErEDiTarY
angioEDEma (HaE) aTTaCKS
Zuraw, B. 1 , Baker, J. 2 , Hurewitz, D. 3 , White, m. 4 , Vegh, A. 5 , Bielory, l. 6 , lumry, W. 7 , riedl , m. 8 , Davis-lorton , m. 9 , levy, r. 10 ,
grant, J. A. 11 , Busse, P. 12 , Banerji, A. 13 , li, H. H. 14 , Kalfus, i. 15 , Broom, C. 16 , Villano, s. 16 , Uknis, m. 16 , tillotson, g. 16 and the Cinryze
study group
1 2 3 4 the scripps research institute, la Jolla, CA. University of michigan, Ann Arbor, mi. Allergy Clinic of tulsa, inc., tulsa, OK. institute
for Asthma and Allergy, Wheaton, mD. 5Puget sound Allergy Asthma and imm., tacoma, WA. 6UmDnJ - new Jersey medical school,
newark, nJ. 7Allergy and Asthma specialists, Dallas, tX. 8UClA medical Center, los Angeles, CA. 9Winthrop - University Hospital,
mineola, nY. 10Family Allergy and Asthma Center, PC, Atlanta, gA. 11University texas medical Branch, galveston, tX. 12mount sinai
school of medicine, new York, nY. 13massachusetts general Hospital, Boston, mA. 14institute for Asthma & Allergy, Chevy Chase, mD.
15 16 lev Pharmaceuticals, Plymouth meeting, PA. ViroPharma incorporated, Exton, PA.
www.worldallergy.org 136
FinAl PrOgrAm